27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Dr. Gary S. Jacob, CEO of OKYO Pharma (NASDAQ:OKYO), was recently a guest on Benzinga’s All Access.
OKYO Pharma is a biotechnology company focused on the treatment of ocular diseases. OKYO is currently developing OK-101 to treat dry eye disease, which is a currently underserved and untreated condition affecting millions of people in the U.S. According to the company, the addressable market exceeds $5 billion.
OK-101 has just had its First Patient First Visit, marking the beginning of its phase 2 trials. The company is very excited about this event and says it expects top line data by the end of the year.
Watch the full interview here:
Featured photo by v2osk on Unsplash.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!